Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients With Relapsed and Refractory Non-Hodgkin Lymphoma

NCT03210662 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03210662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03210662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients With Relapsed and Refractory Non-Hodgkin Lymphoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2018
Completion date
October 31, 2025
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary mediastinal (thymic) large b-cell lymphoma, recurrent aggressive non-hodgkin lymphoma, recurrent mature t- cell and nk-cell non-hodgkin lymphoma, recurrent non-hodgkin lymphoma, recurrent t-cell non-hodgkin lymphoma, recurrent transformed follicular lymphoma to diffuse large b-cell lymphoma, refractory aggressive non-hodgkin lymphoma, refractory non-hodgkin lymphoma, refractory t-cell non-hodgkin lymphoma, refractory transformed follicular lymphoma to diffuse large b-cell lymphoma, transformed marginal zone lymphoma to diffuse large b-cell lymphoma